Login to Your Account



Investors Spooked; HGSI Shares Fall

Benlysta's Modest Benefit vs. Risks Poses Dilemma

By Donna Young


Monday, November 15, 2010
WASHINGTON – Shares of Human Genome Sciences Inc. tumbled 10.9 percent Friday after FDA drug reviewers questioned whether the modest benefit of Benlysta (belimumab) in treating some lupus patients is worth the potential increased risk of death, infection or adverse neuropsychiatric effects, including suicide. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription